Mostrar el registro sencillo del ítem

dc.contributor.author
Perez Lloret, Santiago  
dc.contributor.author
Rey, María Verónica  
dc.contributor.author
Dellapina, Estelle  
dc.contributor.author
Pellaprat, Jean  
dc.contributor.author
Brefel Courbon, Christine  
dc.contributor.author
Rascol, Olivier  
dc.date.available
2023-05-05T16:38:41Z  
dc.date.issued
2012-06  
dc.identifier.citation
Perez Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel Courbon, Christine; et al.; Emerging analgesic drugs for Parkinson's disease; Informa Healthcare; Expert Opinion on Emerging Drugs; 17; 2; 6-2012; 1-15  
dc.identifier.issn
1472-8214  
dc.identifier.uri
http://hdl.handle.net/11336/196493  
dc.description.abstract
Introduction: Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition. Areas covered: Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed. Expert opinion: Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Informa Healthcare  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
ANALGESIC TREATMENTS  
dc.subject
BOTULINUM TOXIN  
dc.subject
CRANIAL ELECTROTHERAPY STIMULATION  
dc.subject
DOPAMINE AGONISTS  
dc.subject
DULOXETINE  
dc.subject
LEVODOPA  
dc.subject
NON-MOTOR SYMPTOMS  
dc.subject
OUTCOME EVALUATION  
dc.subject
PAIN  
dc.subject
PARKINSON'S DISEASE  
dc.subject
PATIENT SELECTION  
dc.subject
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION  
dc.subject
SURGICAL TREATMENTS FOR PD  
dc.subject.classification
Neurología Clínica  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Emerging analgesic drugs for Parkinson's disease  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-05-05T12:53:27Z  
dc.journal.volume
17  
dc.journal.number
2  
dc.journal.pagination
1-15  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina  
dc.description.fil
Fil: Rey, María Verónica. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina  
dc.description.fil
Fil: Dellapina, Estelle. Université Toulouse III Paul Sabatier; Francia  
dc.description.fil
Fil: Pellaprat, Jean. Université Toulouse III Paul Sabatier; Francia  
dc.description.fil
Fil: Brefel Courbon, Christine. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia  
dc.description.fil
Fil: Rascol, Olivier. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia  
dc.journal.title
Expert Opinion on Emerging Drugs  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14728214.2012.677949  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1517/14728214.2012.677949